Chief Development Officer, Glaukos
Search every verified Tomas Navratil interview, podcast appearance, and on-the-record quote — each transcript cross-checked by AI and human review to confirm speaker identity. Tomas Navratil, Chief Development Officer at Glaukos, presented an update on the company’s research and development strategy at an industry event in September 2023. He discussed recent regulatory clearances and clinical trial results, including the 510(k) clearance of the iStent infinite, which he described as the first standalone administration of a trabecular bypass device. Navratil also highlighted positive Phase 3 results for the iDose TR travoprost implant, noting that in two studies involving over 1,100 patients, 93% were well controlled at 12 months after a single dose on the same or fewer topical medications, and 81% were medication-free. He characterized the safety profile as showing no serious corneal adverse events and a hyperemia rate of 3%, which he said was more than tenfold lower than that associated with topical travoprost. Navratil stated that Glaukos’s R&D strategy is based on five therapeutic platforms, which he said are capable of generating therapies for glaucoma, dry eye disease, presbyopia, keratoconus, age-related macular degeneration, diabetic macular edema, retinal vein occlusion, and other ophthalmic conditions. He noted that the company’s near-term pipeline includes the iDose TR in a pre-NDA stage and a second-generation product, iDose TREX, with twice the payload. Navratil attributed the company’s progress to support from patients and clinicians, and said Glaukos is preparing for future growth following recent approvals and positive study results.
“Glaukos was initially created with the intent on transforming glaucoma therapy and Innovation is truly at the heart of everything that we do at Glaukos.”
“This effort led to a creation of new medical device class, the tropical bypass devices or makes the first in class product I stand and ultimately the global mix Marketplace.”
“The R&D strategy for future growth and value creation is really based on utilizing these technological platforms, each of which alone has the potential of spawning multiple paradigm shifting products and are they able to be then leveraged in our scalable commercial platform.”
“The iDos is a miniature implant implanted in the anterior segment of the eye and capable of eluting multiple years of pharmacotherapy into the anterior segment.”
“I would like to highlight the strength of the iDose infinite pivotal results based on this clinical trial that supported the 510k clearance of this first standalone administration of a mixed device.”
“In these two large well-controlled studies studying over 1100 patients, more than quarter of the patients came in on more than two IOP lowering medications at baseline. Despite this robust pharmacotherapy at 12 months we were still able to demonstrate that 93% of patients were well controlled at 12 months after a singl...”
“Importantly, the safety and tolerability in this trial was excellent, demonstrating no serious corneal adverse events, no adverse events of peril fat atrophy and industry best in class three percent hyperemia rate which is more than tenfold lower than topical hyperemia due to topical chavatanzi.”
“These five Glaukos therapeutic platforms are truly capable of generating waves of novel paradigm shifting therapies targeting not only glaucoma but also dry disease, presbyopia, keratoconus, AMD, DME, RVO and host of other orphan ophthalmic diseases.”
“Given the recent success and approvals of iDose infinite, iPromix combined with the two positive sets of studies in phase three supporting iDose NDA submission, the occurring forward high degree of forward momentum as we deliver and execute on our R&D strategy preparing for future growth.”
Website: https://ois.net FOLLOW Ophthalmology Innovation Source On Social Media: ▻ LinkedIn: ...
Sign in to search the full transcript archive, filter by topic, and access every quote from Tomas Navratil.
The summary and quote tags on this profile are produced with AI assistance from verified, first-person interview transcripts, then checked by our team to confirm the speaker's identity and the accuracy of every quote. See how we verify →